Multiple studies highlight the integration of AI in drug discovery and cancer research. KAIST developed an AI model for autonomous design of drug candidates targeting cancer mutations. Meanwhile, Tahoe Therapeutics raised $30 million to create a billion-cell dataset for training AI models of living cells. Additionally, novel molecular targets and AI methods are improving drug combination therapy predictions, offering enhanced precision medicine strategies.